Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) major shareholder Coastlands Capital Lp bought 33,094 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was purchased at an average price of $5.89 per share, with a total value of $194,923.66. Following the purchase, the insider directly owned 495,510 shares of the company’s stock, valued at $2,918,553.90. The trade was a 7.16% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Coastlands Capital Lp also recently made the following trade(s):
- On Tuesday, November 17th, Coastlands Capital Lp bought 20,000 shares of Bolt Biotherapeutics stock. The stock was acquired at an average cost of $5.75 per share, for a total transaction of $115,000.00.
- On Monday, November 9th, Coastlands Capital Lp purchased 50,000 shares of Bolt Biotherapeutics stock. The shares were acquired at an average price of $6.38 per share, for a total transaction of $319,000.00.
Bolt Biotherapeutics Stock Down 0.8%
NASDAQ BOLT opened at $5.06 on Friday. The stock’s 50 day simple moving average is $4.75 and its 200 day simple moving average is $4.50. Bolt Biotherapeutics, Inc. has a one year low of $3.10 and a one year high of $7.78. The firm has a market cap of $13.21 million, a PE ratio of -0.34 and a beta of 0.85. The company has a debt-to-equity ratio of 2.06, a current ratio of 2.05 and a quick ratio of 2.61.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($2.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.68) by $1.43. The firm had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.45 million. Bolt Biotherapeutics had a negative return on equity of 154.11% and a negative net margin of 611.47%. As a group, sell-side analysts forecast that Bolt Biotherapeutics, Inc. will post -11.10 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $14.50.
Get Our Latest Stock Report on Bolt Biotherapeutics
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd acquired a new stake in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics comprises approximately 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th largest holding. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 86.70% of the company’s stock.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics is a clinical-stage biotechnology company based in Redwood City, California. It develops immunotherapies designed to direct the body’s immune system against cancer. The company’s Boltbody platform is designed to pair tumor-targeting antibodies with immune-stimulating components. Its pipeline has included BDC-3042, an investigational antibody intended to activate macrophages, immune cells that can help recognize and attack tumors. Bolt has also developed BDC-1001, an investigational HER2-targeting immune-stimulating antibody conjugate.
Read More
- Five stocks we like better than Bolt Biotherapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
